(Q29620313)

title

Natural innate and adaptive immunity to cancer (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

30 April 2017

Natural Innate and Adaptive Immunity to Cancer (English)

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

1

Matthew D. Vesely

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21219185

21 November 2024

2

Michael H. Kershaw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21219185

21 November 2024

4

Mark J. Smyth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21219185

21 November 2024

Robert D. Schreiber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21219185

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

21 November 2024

language of work or name

1 reference

30 April 2017

publication date

2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

full work available at URL

30 April 2017

http://arjournals.annualreviews.org/doi/abs/10.1146/annurev-immunol-031210-101324

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21219185

https://www.annualreviews.org/doi/pdf/10.1146/annurev-immunol-031210-101324

21 November 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Annual Review of Immunology

21 November 2024

published in

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

30 April 2017

volume

29

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

30 April 2017

page(s)

235-71

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

30 April 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

21 November 2024

2

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cell death: critical control points

21 November 2024

3

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The CD95(APO-1/Fas) DISC and beyond

21 November 2024

4

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

The Hallmarks of Cancer

5

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

New roles for integrins in squamous-cell carcinoma

21 November 2024

6

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer

21 November 2024

7

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer immunoediting: from immunosurveillance to tumor escape

21 November 2024

8

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 November 2024

9

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Nederlands Tijdschrift voor Geneeskunde

21 November 2024

10

5

273

Ehrlich P.

1909

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications

21 November 2024

11

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

21 November 2024

13

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 November 2024

14

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice

21 November 2024

16

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 November 2024

17

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

21 November 2024

18

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 November 2024

19

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 November 2024

20

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regulation of cutaneous malignancy by gammadelta T cells

21 November 2024

21

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The immunobiology of cancer immunosurveillance and immunoediting

21 November 2024

22

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The three Es of cancer immunoediting

21 November 2024

23

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Interferons, immunity and cancer immunoediting

21 November 2024

24

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 November 2024

25

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Immune surveillance of tumors

21 November 2024

26

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

21 November 2024

27

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer

21 November 2024

28

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Type I natural killer T cells suppress tumors caused by p53 loss in mice

21 November 2024

29

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

21 November 2024

30

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

21 November 2024

31

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A critical function for type I interferons in cancer immunoediting

21 November 2024

32

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function

21 November 2024

33

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis

21 November 2024

34

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 November 2024

35

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 November 2024

36

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent

21 November 2024

37

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Accelerated tumor growth in mice deficient in DNAM-1 receptor

21 November 2024

38

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

NKG2D function protects the host from tumor initiation

21 November 2024

39

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 November 2024

40

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor immunoediting by NKp46.

21 November 2024

41

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

TAP expression provides a general method for improving the recognition of malignant cells in vivo

21 November 2024

42

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

21 November 2024

44

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction

21 November 2024

45

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma

21 November 2024

46

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model.

21 November 2024

47

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

MK2 regulates the early stages of skin tumor promotion.

21 November 2024

48

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

RAGE signaling sustains inflammation and promotes tumor development

21 November 2024

50

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

21 November 2024

51

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis

21 November 2024

52

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 November 2024

53

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 November 2024

54

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis

21 November 2024

55

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

21 November 2024

56

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IL-23 promotes tumour incidence and growth

21 November 2024

57

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis

21 November 2024

58

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation

21 November 2024

59

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

61

50

3851

Ward PL

1990

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells

21 November 2024

62

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies

21 November 2024

63

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions

21 November 2024

64

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer

21 November 2024

65

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Immunodepression and malignancy

21 November 2024

66

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

68

62

24

Hayashi T

2002

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy

21 November 2024

69

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

21 November 2024

70

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

Inflammation and cancer

71

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Perforin-mediated suppression of B-cell lymphoma

21 November 2024

72

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma

21 November 2024

73

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

21 November 2024

74

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells

21 November 2024

75

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 November 2024

76

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Models, mechanisms and clinical evidence for cancer dormancy

21 November 2024

77

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Adaptive immunity maintains occult cancer in an equilibrium state

21 November 2024

78

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.

21 November 2024

80

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells

21 November 2024

81

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

21 November 2024

82

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma

21 November 2024

83

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)

21 November 2024

84

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis

21 November 2024

85

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 November 2024

86

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 November 2024

87

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A central role for central tolerance

21 November 2024

88

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

89

60

3002

Schell TD

2000

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 November 2024

90

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

21 November 2024

91

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo

21 November 2024

92

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

21 November 2024

93

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D.

21 November 2024

94

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 November 2024

95

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

21 November 2024

97

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

98

61

4942

Shin MS

2001

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

FAS Death Domain Deletions and Cellular FADD-like Interleukin 1 Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes

21 November 2024

99

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 November 2024

100

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Non-classical HLA-G antigen and its role in the cancer progression

21 November 2024

101

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells

21 November 2024

102

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

21 November 2024

103

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo

21 November 2024

104

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 November 2024

105

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

21 November 2024

106

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Lipid accumulation and dendritic cell dysfunction in cancer

21 November 2024

107

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Transforming growth factor-beta and the immune response: implications for anticancer therapy

21 November 2024

109

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ

21 November 2024

111

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

21 November 2024

112

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 November 2024

113

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 November 2024

114

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Immunoregulatory T cells in tumor immunity

21 November 2024

115

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regulatory T cells: how do they suppress immune responses?

21 November 2024

116

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion

21 November 2024

117

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer

21 November 2024

118

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

21 November 2024

119

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Myeloid-derived suppressor cells as regulators of the immune system

21 November 2024

120

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

21 November 2024

121

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 November 2024

122

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 November 2024

123

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 November 2024

124

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

21 November 2024

125

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

21 November 2024

126

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A

21 November 2024

127

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

21 November 2024

128

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Macrophage polarization in tumour progression

21 November 2024

129

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 November 2024

130

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Aids-related malignancies

21 November 2024

131

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Association of Cancer With AIDS-Related Immunosuppression in Adults

21 November 2024

132

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Elevated risk of lung cancer among people with AIDS.

21 November 2024

133

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

HIV infection is associated with an increased risk for lung cancer, independent of smoking

21 November 2024

134

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer incidence before and after kidney transplantation

21 November 2024

135

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A population-based study of skin cancer incidence and prevalence in renal transplant recipients

21 November 2024

136

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Malignant melanoma in organ allograft recipients

21 November 2024

137

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The incidence of cancer in a population-based cohort of Canadian heart transplant recipients.

21 November 2024

138

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Solid tumors after heart transplantation: lethality of lung cancer

21 November 2024

139

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries

21 November 2024

140

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Risk of malignant neoplasms after liver transplantation: a population-based study

21 November 2024

141

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Immunosuppressive regimen influences incidence of skin cancer in renal and pancreatic transplant recipients

21 November 2024

142

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Incidence of and risk factors for skin cancer after heart transplant

21 November 2024

143

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature

21 November 2024

144

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells

21 November 2024

145

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cell surface antigens of human renal cancer defined by autologous typing

21 November 2024

146

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A systematic review of humoral immune responses against tumor antigens

21 November 2024

147

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events

21 November 2024

148

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

149

60

1777

Soussi T.

2000

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion

21 November 2024

150

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

21 November 2024

151

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures

21 November 2024

152

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

21 November 2024

153

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

21 November 2024

154

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay

21 November 2024

155

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 November 2024

156

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Paraneoplastic neurological degenerations: keys to tumour immunity

21 November 2024

157

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-specific killer cells in paraneoplastic cerebellar degeneration

21 November 2024

158

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET.

21 November 2024

159

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies

21 November 2024

160

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Spontaneous remission of small cell lung cancer: a case report and review in the literature

21 November 2024

161

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Model predicting survival in stage I melanoma based on tumor progression

21 November 2024

162

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

21 November 2024

163

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

164

61

3932

Schumacher K

2001

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 November 2024

165

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 November 2024

166

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

167

58

3491

Naito Y

1998

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 November 2024

168

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 November 2024

169

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

170

4

1

Scanlan MJ

2004

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression

21 November 2024

171

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 November 2024

172

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 November 2024

173

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions

21 November 2024

174

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 November 2024

175

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 November 2024

176

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases

21 November 2024

177

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability

21 November 2024

178

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma

21 November 2024

180

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value

21 November 2024

181

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Dormancy of mammary carcinoma after mastectomy

21 November 2024

182

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Circulating tumor cells in patients with breast cancer dormancy

21 November 2024

183

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Transplant tumor registry: donor related malignancies

21 November 2024

184

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery

21 November 2024

185

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Immune response to premalignancy: insights from patients with monoclonal gammopathy

21 November 2024

186

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy

21 November 2024

187

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Origin and physiological roles of inflammation

21 November 2024

189

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Inflammation and cancer: back to Virchow?

21 November 2024

190

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

21 November 2024

191

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Interleukin-1β–Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen–Induced Tumors

21 November 2024

192

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The impact of regulatory T cells on carcinogen-induced sarcogenesis

21 November 2024

193

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

21 November 2024

194

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88

21 November 2024

195

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 November 2024

196

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 November 2024

197

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 November 2024

198

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

21 November 2024

200

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 November 2024

201

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 November 2024

202

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas

21 November 2024

203

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Decreased tumor surveillance in perforin-deficient mice

21 November 2024

204

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice

21 November 2024

205

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18

21 November 2024

206

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts

21 November 2024

207

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

21 November 2024

208

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-IMMUNOL-031210-101324

21 November 2024

Identifiers

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

30 April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21219185

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017